Airway Therapeutics, an Ohio LLC, is bringing to market a novel recombinant human surfactant protein, human Surfactant Protein D (rhSP-D), for use in a number of indications affecting the lung in preterm babies which will significantly improve clinical outcomes and drastically lower the costs after treatment without changing current hospital procedures.